APA (7th ed.) Citation

Erkens, R. G. A., Calis, J. J. A., Verwoerd, A., De Roock, S., Ter Haar, N. M., Den Engelsman, G., . . . Vastert, S. J. (2024). Recombinant Interleukin‐1 Receptor Antagonist Is an Effective First‐Line Treatment Strategy in New‐Onset Systemic Juvenile Idiopathic Arthritis, Irrespective of HLA‐DRB1 Background and IL1RN Variants. Arthritis & rheumatology (Hoboken, N.J.), 76(1), 119-129. https://doi.org/10.1002/art.42656

Chicago Style (17th ed.) Citation

Erkens, Remco G. A., et al. "Recombinant Interleukin‐1 Receptor Antagonist Is an Effective First‐Line Treatment Strategy in New‐Onset Systemic Juvenile Idiopathic Arthritis, Irrespective of HLA‐DRB1 Background and IL1RN Variants." Arthritis & Rheumatology (Hoboken, N.J.) 76, no. 1 (2024): 119-129. https://doi.org/10.1002/art.42656.

MLA (9th ed.) Citation

Erkens, Remco G. A., et al. "Recombinant Interleukin‐1 Receptor Antagonist Is an Effective First‐Line Treatment Strategy in New‐Onset Systemic Juvenile Idiopathic Arthritis, Irrespective of HLA‐DRB1 Background and IL1RN Variants." Arthritis & Rheumatology (Hoboken, N.J.), vol. 76, no. 1, 2024, pp. 119-129, https://doi.org/10.1002/art.42656.